Pfizer announces Phase 3 S-TRAC clinical trial results
Pfizer announced results from the Phase 3 S-TRAC clinical trial, or Sunitinib Trial as Adjuvant Treatment of Renal Cancer, investigating SUTENT as adjuvant therapy. The trial showed SUTENT extended disease-free survival, or DFS, by more than one year versus placebo in patients who were at high risk for recurrence after surgical resection of renal cell carcinoma, or RCC. These results will be presented today during a Presidential Symposium at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology being held in Copenhagen, Denmark. The results have also been published online by The New England Journal of Medicine. Adjuvant therapies are treatments that can be given to reduce the likelihood of the cancer returning after initial treatment such as surgery. The results from the S-TRAC trial showed that after one year of treatment, the median time until disease recurrence in participants treated with SUTENT after surgery was 6.8 years compared with 5.6 years for patients treated with placebo as assessed by independent central review, resulting in an overall risk reduction of 24 percent. At the time of the analysis, overall survival data was immature. Based on the results of S-TRAC, Pfizer is in discussions with global regulatory authorities to determine potential next steps.